Atai Life Sciences Valued At More Than $3 Billion After IPO
German psychedelic pharmaceutical company Atai Life Sciences is valued at more than $3 billion after its IPO listing on the Nasdaq.
ipo
27 Publicly-Traded Psychedelic Stocks Investors Have Their Eyes On
These psychedelic stocks are all publicly trading. Take a look at the companies leading the psychedelic medicine revolution.
Peter Thiel-Backed Atai Life Sciences Announces IPO With $2 Billion Valuation
Atai Life Sciences is the latest psychedelic company to announce plans to IPO. The Peter Thiel-backed biotech startup is valued at more than $2 billion.
Field Trip Health Begins Trading on TSE, Sets Sights on Nasdaq
Psychedelic lifestyle brand Field Trip Health is now trading on the Toronto Stock Exchange under the symbol “FTRP”.
Psychedelic Platform Field Trip Health Gets Uplisting Conditional Approval for Toronto Stock Exchange
Psychedelic healing platform Field Trip Health has received conditional approval to uplist to the Toronto Stock Exchange.
Psychedelic Drug Development Company Mynd Life Sciences Goes Public on the CSE
Psychedelic drug development company Mynd Life Sciences has gone public on the CSE.
Psychedelic Investment Platform Clarify Pharma to Go Public With £10.5 Million Valuation
The psychedelic investment platform Clarify Pharma is expecting to go public on the AQSE with a valuation of £10.5 million.
End of content
End of content